Inhibikase Therapeutics (IKT) Consolidated Net Income (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Consolidated Net Income data on file, last reported at -$17.8 million in Q1 2026.

• On a quarterly basis, Consolidated Net Income fell 22.21% year-over-year to -$17.8 million in Q1 2026; TTM through Mar 2026 was -$63.0 million, a 62.47% decrease from a year earlier, with the FY2025 full-year figure at -$83.6 million, down 40.11% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$17.8 million, up from -$21.5 million in the prior quarter.
• Over the last five years, Consolidated Net Income for IKT reached as high as -$4.3 million in Q4 2022 and fell as low as -$21.5 million in Q4 2025.
• Historically, Consolidated Net Income has averaged -$8.5 million across 5 years, with a median of -$5.2 million in 2024.
• Across the five-year window, Consolidated Net Income grew 16.05% in 2024 and tumbled 204.12% in 2025, its largest moves.
• Year by year, Consolidated Net Income stood at -$4.3 million in 2022, then retreated by 1.58% to -$4.4 million in 2023, then slumped by 193.6% to -$12.9 million in 2024, then tumbled by 66.11% to -$21.5 million in 2025, then advanced by 16.92% to -$17.8 million in 2026.
• Per Business Quant data, the three most recent Consolidated Net Income figures were -$17.8 million in Q1 2026, -$21.5 million in Q4 2025, and -$12.8 million in Q3 2025.